There is no benefit in the use of postnatal intravenous immunoglobulin for the prevention of relapses of multiple sclerosis: findings from a systematic review and meta-analysis



Título del documento: There is no benefit in the use of postnatal intravenous immunoglobulin for the prevention of relapses of multiple sclerosis: findings from a systematic review and meta-analysis
Revista: Arquivos de neuro-psiquiatria
Base de datos: PERIÓDICA
Número de sistema: 000419843
ISSN: 0004-282X
Autores: 1
1
2
2
2
2
Instituciones: 1Harvard Medical School, Spaulding-Labuschagne Neuromodulation Center, Boston, Massachusetts. Estados Unidos de América
2Universidade Metropolitana de Santos, Departamento de Neurologia, Santos, Sao Paulo. Brasil
Año:
Periodo: Jun
Volumen: 76
Número: 6
Paginación: 361-366
País: Brasil
Idioma: Inglés
Tipo de documento: Revisión bibliográfica
Enfoque: Analítico
Resumen en inglés Multiple sclerosis (MS) is a complex autoimmune and neurodegenerative disease of the central nervous system. Since MS affects mostly fertile women, pregnancy issues often arise in daily practice. The present study assessed the use of postpartum intravenous immunoglobulin (IVIG) in MS. Methods The authors individually searched for records using PubMed, Medline, EMBASE, Cochrane, SciELO, LILACS, and Google Scholar, using the terms “multiple sclerosis” OR “MS” AND “pregnancy” OR “gestation” OR “partum” OR “post-partum” OR “puerperium” AND “immunoglobulin”. Results The initial search returned 321 papers. There were 11 eligible articles selected for the review. In total, 380 patients had received post-natal IVIG to reduce the number of postpartum relapses. The unadjusted number needed to treat was 6.3 for the quantitative and 5.8 for the qualitative analyses. Conclusion The therapeutic effect of IVIG for prevention of postnatal relapses in MS could not clearly be established in this meta-analysis
Resumen en portugués Esclerose múltipla (EM) é uma complexa doença autoimune e neurodegenerativa do sistema nervoso central. Uma vez que EM afeta principalmente mulheres em idade fértil, assuntos relacionados à gravidez frequentemente surgem na prática diária. O presente estudo avaliou o uso pós-parto de imunoglobulina (IVIG) na EM. Métodos Os autores individualmente pesquisaram as bases de dados PubMed, Medline, EMBASE, Cochrane, SciELO, LILACS, e Google Scholar usando os termos “multiple sclerosis” OR “MS” AND “pregnancy” OR “gestation” OR “partum” OR “post-partum” OR “puerperium” AND “immunoglobulin”. Resultados A pesquisa inicial retornou 321 artigos. Havia 11 artigos elegíveis para a revisão. No total, havia relato de 380 pacientes que receberam IVIG após a gravidez visando reduzir o número de surtos. O número necessário para tratar não a
Disciplinas: Medicina
Palabras clave: Neurología,
Ginecología y obstetricia,
Terapéutica y rehabilitación,
Esclerosis múltiple,
Embarazo,
Inmunoglobulinas
Keyword: Neurology,
Gynecology and obstetrics,
Therapeutics and rehabilitation,
Multiple sclerosis,
Pregnancy,
Immunoglobulins
Texto completo: Texto completo (Ver HTML)